Tern Plc CEO Albert Sisto increases interest in company

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, announced today that on the 23rd August 2022, the Company entered into a direct subscription with Albert Sisto, Chief Executive Officer, via the Albert E Sisto Revocable Trust, for a total of 200,000 new Ordinary Shares of 0.02p pence each at an issue price of 9.9p pence per share.

The Subscription has been undertaken by the Company to allow Mr. Sisto to increase his interest in the Company, which is otherwise difficult for Mr. Sisto to do, due to his primary residency and tax status in the United States of America. The Issue Price is equal to the closing mid-market price of the Company’s Ordinary Shares on AIM on the business day prior to this announcement.

Albert Sisto’s total beneficial interest following this transaction will be 10,616,666 Ordinary Shares, representing approximately 3.01% of the voting rights in the Company’s enlarged share capital following the issue of the Subscription Shares. The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation, is appended below.

Application has been made for the 200,000 Subscription Shares to be admitted to trading on AIM, which is expected to take place on or around 30th August 2022. Once issued, the Subscription Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Total Voting Rights

Following Admission, the Tern plc issued ordinary share capital will consist of 352,214,701 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 352,214,701. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search